Calidi Biotherapeutics Inc. (CLDI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Calidi Biotherapeutics Inc. stock (CLDI) is currently trading at $0.28. Calidi Biotherapeutics Inc. PE ratio is 0.79. Calidi Biotherapeutics Inc. PS ratio (Price-to-Sales) is 50.83. Analyst consensus price target for CLDI is $120.00. WallStSmart rates CLDI as Sell.
- CLDI PE ratio analysis and historical PE chart
- CLDI PS ratio (Price-to-Sales) history and trend
- CLDI intrinsic value — DCF, Graham Number, EPV models
- CLDI stock price prediction 2025 2026 2027 2028 2029 2030
- CLDI fair value vs current price
- CLDI insider transactions and insider buying
- Is CLDI undervalued or overvalued?
- Calidi Biotherapeutics Inc. financial analysis — revenue, earnings, cash flow
- CLDI Piotroski F-Score and Altman Z-Score
- CLDI analyst price target and Smart Rating
Calidi Biotherapeutics Inc.
📊 No data available
Try selecting a different time range
CLDI Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Calidi Biotherapeutics Inc. (CLDI)
CLDI trades at a significant discount to its Graham intrinsic value of $2.45, offering a 67% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Calidi Biotherapeutics Inc. (CLDI) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and price/sales. Significant fundamental concerns warrant caution or avoidance.
Calidi Biotherapeutics Inc. (CLDI) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Calidi Biotherapeutics Inc. (CLDI) Areas to Watch (3)
Very expensive at 50.8x annual revenue
Very low institutional interest at 4.33%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Calidi Biotherapeutics Inc. (CLDI) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.39) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Institutional Own., Market Cap. Some valuation metrics including Price/Sales (50.83) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLDI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLDI's Price-to-Sales ratio of 50.83x trades at a deep discount to its historical average of 359.87x (7th percentile). The current valuation is 97% below its historical high of 1677.24x set in Jul 2023, and 99% above its historical low of 25.6x in Apr 2024. Over the past 12 months, the PS ratio has compressed from ~103.5x as trailing revenue scaled faster than the stock price.
Insider Transactions
Loading insider activity...
About Calidi Biotherapeutics Inc.(CLDI)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California.